New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 650.46mg equivalent to darunavir 600 mg - film coated tablet - 600 mg - active: darunavir ethanolate 650.46mg equivalent to darunavir 600 mg excipient: crospovidone magnesium stearate opadry orange 85f13962 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - darunavir ethanolate 81.31mg equivalent to darunavir 75 mg - film coated tablet - 75 mg - active: darunavir ethanolate 81.31mg equivalent to darunavir 75 mg excipient: colloidal silicon dioxide crospovidone magnesium stearate opadry white 85f18422 purified water silicified microcrystalline cellulose - adult patients: prezista (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base; galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base - modified release capsule - 16 mg - active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 20.51mg equivalent to 16 mg galatamine base excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg; galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg - modified release capsule - 24 mg - active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose iron oxide red iron oxide yellow opacode black s-1-277002 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 30.76mg equivalent to galantamine base 24 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg; galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg - modified release capsule - 8 mg - active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-27794 opadry clear oy-7240 sugar spheres titanium dioxide active: galantamine hydrobromide 10.25mg equivalent to galantamine base 8 mg excipient: diethyl phthalate ethylcellulose gelatin hypromellose opacode black s-1-277002 opadry clear oy-7240 sugar spheres - reminyl is indicated for the treatment of mild to moderately severe dementia of the alzheimer type.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 0.25mg;  ;   - film coated tablet - 0.25 mg - active: risperidone 0.25mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 iron oxide yellow lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate titanium dioxide

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 0.5mg;  ;   - film coated tablet - 0.5 mg - active: risperidone 0.5mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 iron oxide red lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 1mg;  ;   - film coated tablet - 1 mg - active: risperidone 1mg     excipient: colloidal silicon dioxide hypromellose e-15 hypromellose e-5 lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified water sodium laurilsulfate - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 2mg;  ;   - film coated tablet - 2 mg - active: risperidone 2mg     excipient: colloidal silicon dioxide hypromellose   lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc sodium laurilsulfate sunset yellow fcf titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 3mg;  ;   - film coated tablet - 3 mg - active: risperidone 3mg     excipient: colloidal silicon dioxide hypromellose   lactose monohydrate magnesium stearate maize starch microcrystalline cellulose propylene glycol purified talc quinoline yellow sodium laurilsulfate titanium dioxide - risperdal is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent.